eCAM Advance Access published online on October 27, 2004
eCAM, doi:10.1093/ecam/neh045
Copyright © 2004 by the Oxford University Press.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Division of Persistent and Oncogenic Viruses, Center for Chronic Viral Disease, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan
* To whom correspondence should be addressed. We examined the effect of three types of Kampo medicines on human cytomegalovirus (CMV) replication in the human embryonic fibroblast cell line, MRC-5. Treatment of cells with at least 0.01 µg/ml of Kampo medicines inhibited the cytopathic effects of CMV-infected MRC-5 cells. Moreover, Kampo medicine decreased the replication of CMV without affecting the inhibition of host cells, with a concomitant decrease in CMV DNA levels. However, Kampo medicine demonstrated no virocidal effect on cell-free CMV. Furthermore, western blotting analysis demonstrated that the Kampo medicine decreased the amount of 65 kDa late antigen expression in the infected cells. These results suggest that Kampo medicine may be sufficient to inhibit viral DNA replication and late protein synthesis, resulting in anti-CMV effects. Therefore, these three Kampo medicines have the potential of being a source of new powerful anti-CMV compounds.
Revised July 9, 2004
Accepted August 30, 2004
Original Article
In Vitro Anti-Cytomegalovirus Activity of Kampo (Japanese Herbal) Medicine
2 Department of Serology, Kanazawa Medical University, Uchinada, Ichikawa 920-0293, Japan
Tsugiya Murayama, E-mail: t-mura{at}m3.kufm.kagoshima-u.ac.jp
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
E. L. Cooper eCAM: Clinical Analyses and Increasing Visibility Evid. Based Complement. Altern. Med., March 1, 2009; 6(1): 1 - 2. [Full Text] [PDF] |
||||
